Glaxosmithkline Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/93425ou5au1wydk8mqi6xb44.pdf

Key Takeaways


Volume-Led Growth Engine

Bhushan Akshikar: "Clearly, what defines the success of some of these iconic assets that we have in the general medicines portfolio is the science behind why some of these brands continue to be, as I keep saying, not trademarks, but these are trust marks."

Oncology: The Next Growth Platform


Shingrix & Adult Vaccination Ecosystem

Bhushan Akshikar: "I always say it's not a 100-meter sprint. It's an endurance sport where every quarter, every year you're learning, you're creating something different."

Respiratory & Specialty Portfolio


Margins, Cash & Investment Capacity

Bhushan Akshikar: "Our endeavour will be to sustain that margin, annual margin as opposed to seeing any opportunities for further expansion. Having said that, I think, which also means our ability to invest in the new business line, especially in the high growth areas like oncology."

Pipeline & Long-Term Bets

Bhushan Akshikar: "I'm not going to focus only on the next five years. I think the organization has outlived generations based on the trust. So, that's where our focus will be."

Guidance & Commitments

CommitmentSpecificsTimeline
Oncology launchesJemperli (endometrial cancer) and Zejula (ovarian cancer) go off the blockNext month
FY26 growthGrow above the IQVIA-prognosed market growth of 8–9%FY2026
Margin sustainabilitySustain annual EBITDA margin at ~31.4%, no further expansion expectedOngoing
Investment while holding marginsEndeavor to hold margins while investing in oncology and new platformsOngoing
Shingrix progress updatesContinue sharing progress every quarterQuarterly
Volume-led strategyVolume-led growth will continueOngoing
Jemperli first-line pursuitPursue first-line indication for endometrial cancer in line with global strategyUndated, trials ongoing

Key Metrics

MetricQ4 FY25
Revenue₹3,723 cr, +9% YoY (full year), predominantly volume-led
Q4 revenue growth6%, predominantly volume-led
General medicines volume growth8% (full year)
Specialty segment growth35% (full year)
Pediatric vaccines growth10% (Q4), 12% (full year)
EBITDA₹1,169 cr, +30% YoY (full year)
EBITDA margin31.4% (full year), up from 26% last year; Q4 exit margin ~34% per analyst reference
PAT growth36% (Q4), 32% (full year)
EPS growth32% (full year)
Cash on balance sheet~₹2,500 cr, zero debt
Final dividend₹42 per share, in addition to interim dividend
Employment cost as % of sales15.7%
SG&A as % of salesDecreased ~4 percentage points (full year)
Field productivityImproved 9 percentage points (full year)
Portfolio under NLEM price control38%
Shingrix doses~20,000 doses in Q4, touching 10,000 doses in March alone
New growth platforms revenue (Trelegy, Nucala, Shingrix)~₹120–₹130 cr annual revenues
Unique HCP touchpoints (omni-channel)Over 400,000
Distinct HCPs covered face-to-face2,75,000
Reach increase via digitalUp by more than 40% on top of previous coverage
Anti-infectives market external growth~3%
Brands with annual revenue >₹100–₹150 cr11–12 brands
Brands in top 20–30 pharma industry rankingsAt least 3–4, including the number one brand
General medicines local manufacturing99% locally manufactured; one-third from own Nashik site, two-thirds from 20 CMOs
Adult vaccination ecosystem target clinics~4,000 clinics
Indians aged 50+ eligible for shingles preventionMore than 10 to 1.2 crore
Ovarian cancer prevalence~6.6 per lakh population
Oncology launches plannedJemperli (endometrial cancer) and Zejula (ovarian cancer), launching in coming months